Aspen manufacturing is expected to drive the group’s earnings growth in the 2027 financial year, as the company works to replace business lost when a major mRNA production contract ended. Aspen Pharmacare forecasts that manufacturing EBITDA will more than double this year, according to its 2026 integrated report. Sterile Operations Offset Contract Loss In the year to end-June, factory EBITDA…
Tag: insulin
-
Aspen Insulin Approval Advances Local Health Solutions
Aspen Pharmacare has secured a landmark regulatory win after the South African Health Products Regulatory Authority (Sahpra) approved the commercial release of Aspen’s first locally manufactured human insulin batches. The products are cleared for sale in South Africa and other African markets, moving the project from planning into live supply for patients and health systems. Aspen produces the insulin at…
-
Aspen Unlocking Value with New Manufacturing Strategies
Aspen Pharmacare’s CEO, Stephen Saad, has declared that all hands are on deck to overhaul the group’s manufacturing business. He identified the performance of its sterile unit as a significant drag on earnings. This underperformance has caused the market to undervalue the company. This move is part of Aspen’s effort to unlock value for its stakeholders and enhance its market…
-
Competition Commission probes insulin price fixing
The Competition Commission in South Africa has launched a formal investigation into leading insulin manufacturers Novo Nordisk and Sanofi Aventis following serious allegations of anti-competitive conduct. The inquiry was initiated after health activists complained about Novo Nordisk’s decision to cease supplying human insulin pens to the country’s Health Department in 2024. This move has forced thousands of diabetic patients to…